Literature DB >> 1496420

Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle.

M Roman1, J H Axelrod, Y Dai, R K Naviaux, T Friedmann, I M Verma.   

Abstract

We have used retroviral vectors to introduce human or canine factor IX cDNAs into cultured primary murine and canine myoblasts and into the established murine myoblast cell line C2C12. In all cases, the stably infected cells produced biologically active factor IX in culture and secreted detectable amounts into the culture medium both before and after differentiation of the cells into myotubes. Myoblasts and differentiated myotubes are therefore capable of performing all the posttranslational modifications of the coagulation factor required for biological activity. We have grafted the genetically modified myoblasts into skeletal muscles of nude mice and have detected stable levels of circulating human factor IX for up to two months after grafting. We propose that grafting genetically modified primary myoblasts or established myoblast cell lines into skeletal muscle may represent a useful approach to gene therapy for a variety of genetic diseases, including intrinsic muscle disease and defects in circulating proteins as in the hemophilias.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1496420     DOI: 10.1007/bf01233861

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  5 in total

1.  Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system.

Authors:  S T Chen; A Iida; L Guo; T Friedmann; J K Yee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

Review 2.  Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques.

Authors:  M E Hoatlin; S L Kozak; C Spiro; D Kabat
Journal:  J Mol Med (Berl)       Date:  1995-03       Impact factor: 4.599

3.  In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery.

Authors:  K Zatloukal; M Cotten; M Berger; W Schmidt; E Wagner; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

4.  Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo.

Authors:  Y Dai; M Roman; R K Naviaux; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

5.  Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus.

Authors:  S K Tripathy; E Goldwasser; M M Lu; E Barr; J M Leiden
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.